Spots Global Cancer Trial Database for RAD001 Plus Bevacizumab in Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: RAD001 Plus Bevacizumab in Metastatic Melanoma
Official Title: A Phase II Trial of RAD001 Plus Bevacizumab in the Treatment of Patients With Metastatic Melanoma
Study ID: NCT00591734
Conditions
Study Description
Brief Summary: This is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.
Detailed Description: All patients will begin treatment with the same doses of RAD001 and bevacizumab. Patients will receive 6 weeks of treatment, followed by re evaluation. Patients with objective response or stable disease will continue treatment until disease progression. During the study, all patients will receive 10 mg of RAD001 orally daily and 15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks. Fifty-five patients will be enrolled in this multi-centered study
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Florida Cancer Specialists, Fort Myers, Florida, United States
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Gulfcoast Oncology Associates, Saint Petersburg, Florida, United States
Northeast Georgia Medical Center, Gainesville, Georgia, United States
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
St. Louis Cancer Care, Chesterfield, Missouri, United States
Methodist Cancer Center, Omaha, Nebraska, United States
Consultants in Medical Oncology and Hematology, Drexel Hill, Pennsylvania, United States
Chattanooga Oncology & Hematology Associates, Chattanooga, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
South Texas Oncology and Hematology, San Antonio, Texas, United States
Virginia Cancer Institute, Richmond, Virginia, United States
Contact Details
Name: John D. Hainsworth, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
